Presentation is loading. Please wait.

Presentation is loading. Please wait.

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

Similar presentations


Presentation on theme: "GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases."— Presentation transcript:

1 GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. Pancreata were removed from acutely diabetic NOD mice before and after 3 weeks of the treatments indicated plus an additional 5 weeks after treatments were stopped or sooner if the mice were killed because of severe diabetes as shown in Fig. 1. NOD-scid mice provide normal values for pancreatic insulin content (A) and β-cell mass (B). Values are means ± SE. *P < 0.05, **P < 0.01 vs. pretreatment values for the numbers of mice shown in parentheses. Wilma L. Suarez-Pinzon et al. Diabetes 2008;57: ©2008 by American Diabetes Association


Download ppt "GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases."

Similar presentations


Ads by Google